BTIG Upgrades Juno Therapeutics (JUNO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Nasdaq outshines Wall St peers on tech boost, earnings glee
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016
November 3, 2016 9:05 AM EDT-- Updated JCAR017 NHL data to be presented
-- Analyst and Investor Event and Webcast on Monday, December 5, at 8:30 p.m. Pacific Time
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the bodys immune system to revolutionize the treatment of cancer, today announced that seven oral and four poster presentations detailing updated clinical and preclinical results generated in partnership with its collaborators will be presented at the 58th American Society of Hematology (ASH) Annual Meeting. Senior executives will also... More
Juno Therapeutics to Report Third Quarter 2016 Financial Results on Wednesday, November 9
November 2, 2016 4:09 PM EDTSEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the third quarter 2016 on Wednesday, November 9, 2016, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET).
Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 7555725.
The webcast can be... More
